{
  "summary": {
    "total_tests": 8,
    "equivalent_results": 6,
    "different_results": 2,
    "high_significance_differences": 0,
    "medium_significance_differences": 0,
    "low_significance_differences": 0,
    "differences_by_focus": {
      "realistic_clinical_scenarios": 2
    },
    "differences_by_category": {
      "major_clinical_impact": 2
    }
  },
  "test_results": [
    {
      "test_id": "test_1_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {},
        "scenario_name": "elderly_mds_with_tp53",
        "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
        "blasts_percentage": 12,
        "age": 75
      },
      "who_classification": "MDS with biallelic TP53 inactivation",
      "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {'1_x_TP53_mutation_50_percent_vaf': True}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False",
        "Biallelic TP53 detected => MDS with biallelic TP53 inactivation"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 12",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related gene mutation",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "MDS_TP53",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS with biallelic TP53 inactivation",
        "icc_classification": "MDS/AML with myelodysplasia related gene mutation",
        "who_category": "MDS_TP53",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 230,
        "clinical_consequences": [
          "Fundamental disease classification disagreement",
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs",
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: High vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.562755",
      "significance": "critical",
      "clinical_impact_score": 230,
      "clinical_consequences": [
        "Fundamental disease classification disagreement",
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs",
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: High vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {
          "Complex_karyotype": true
        },
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_50_percent_vaf": true
        },
        "qualifiers": {},
        "scenario_name": "elderly_mds_with_tp53",
        "scenario_description": "Elderly patient with MDS and TP53 mutation - classic high-risk scenario",
        "blasts_percentage": 12,
        "age": 75
      }
    },
    {
      "test_id": "test_2_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "young_adult_npm1_aml",
        "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
        "blasts_percentage": 85,
        "age": 28
      },
      "who_classification": "AML with NPM1 mutation",
      "icc_classification": "AML with mutated NPM1",
      "who_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: NPM1",
        "NPM1 => AML with NPM1 mutation",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with NPM1 mutation (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 85",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => NPM1",
        "NPM1 => AML with mutated NPM1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with mutated NPM1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with NPM1 mutation",
        "icc_classification": "AML with mutated NPM1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.562831",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "NPM1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "young_adult_npm1_aml",
        "scenario_description": "Young adult with NPM1+ AML - good prognosis group",
        "blasts_percentage": 85,
        "age": 28
      }
    },
    {
      "test_id": "test_3_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_myeloid_malignancy": "Previous MDS"
        },
        "scenario_name": "aml_with_antecedent_mds",
        "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
        "blasts_percentage": 35
      },
      "who_classification": "AML, myelodysplasia related",
      "icc_classification": "AML with myelodysplasia related gene mutation",
      "who_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "MDS-related mutation(s): SF3B1, RUNX1 => AML, myelodysplasia related",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML, myelodysplasia related (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 35",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts >=20 => remain AML",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with myelodysplasia related gene mutation (ICC 2022)"
      ],
      "who_disease_type": "AML_MDS_RELATED",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML, myelodysplasia related",
        "icc_classification": "AML with myelodysplasia related gene mutation",
        "who_category": "AML_MDS_RELATED",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.562883",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true,
          "RUNX1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {
          "previous_myeloid_malignancy": "Previous MDS"
        },
        "scenario_name": "aml_with_antecedent_mds",
        "scenario_description": "AML evolving from prior MDS - therapy-related scenario",
        "blasts_percentage": 35
      }
    },
    {
      "test_id": "test_4_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "core_binding_factor_aml",
        "scenario_description": "Core-binding factor AML with good prognosis",
        "blasts_percentage": 45
      },
      "who_classification": "AML with RUNX1::RUNX1T1 fusion",
      "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
      "who_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "Detected AML-defining abnormality flags: RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 45",
        "Default classification set to: AML, NOS",
        "ICC AML-defining flags => RUNX1::RUNX1T1",
        "RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "No germline predisposition indicated (review at MDT)",
        "Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)"
      ],
      "who_disease_type": "AML_GENETIC",
      "icc_disease_type": "AML_GENETIC",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "AML with RUNX1::RUNX1T1 fusion",
        "icc_classification": "AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1",
        "who_category": "AML_GENETIC",
        "icc_category": "AML_GENETIC",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.562927",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {
          "RUNX1::RUNX1T1": true
        },
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "core_binding_factor_aml",
        "scenario_description": "Core-binding factor AML with good prognosis",
        "blasts_percentage": 45
      }
    },
    {
      "test_id": "test_5_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "therapy_related_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
        "blasts_percentage": 65
      },
      "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
      "icc_classification": "AML with mutated TP53, therapy related",
      "who_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No MDS-related mutations found.",
        "No MDS-related cytogenetic flags found.",
        "No AML_differentiation provided.",
        "No valid AML_differentiation => unknown differentiation",
        "Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Classification with qualifiers => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "Final classification => Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 65",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "Biallelic TP53 => AML with mutated TP53",
        "Blasts >=20 => remain AML",
        "Detected ICC therapy => therapy related: Cytotoxic chemotherapy",
        "No germline predisposition indicated (review at MDT)",
        "Qualifiers appended => AML with mutated TP53, therapy related (ICC 2022)"
      ],
      "who_disease_type": "AML_THERAPY_RELATED",
      "icc_disease_type": "AML_THERAPY_RELATED",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "Acute myeloid leukaemia, unknown differentiation, previous cytotoxic therapy",
        "icc_classification": "AML with mutated TP53, therapy related",
        "who_category": "AML_THERAPY_RELATED",
        "icc_category": "AML_THERAPY_RELATED",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 130,
        "clinical_consequences": [
          "Targeted therapy eligibility differs: {'tp53'}"
        ],
        "treatment_implications": [
          "TP53-directed therapy considerations"
        ],
        "mrd_implications": [
          "Flow cytometry MRD only for both classifications"
        ],
        "prognostic_implications": [
          "Risk category: Intermediate vs High",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.562988",
      "significance": "critical",
      "clinical_impact_score": 130,
      "clinical_consequences": [
        "Targeted therapy eligibility differs: {'tp53'}"
      ],
      "treatment_implications": [
        "TP53-directed therapy considerations"
      ],
      "mrd_implications": [
        "Flow cytometry MRD only for both classifications"
      ],
      "prognostic_implications": [
        "Risk category: Intermediate vs High",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {
          "1_x_TP53_mutation_del_17p": true
        },
        "qualifiers": {
          "previous_cytotoxic_therapy": "Cytotoxic chemotherapy"
        },
        "scenario_name": "therapy_related_aml_tp53",
        "scenario_description": "Therapy-related AML with TP53 mutation - poor prognosis",
        "blasts_percentage": 65
      }
    },
    {
      "test_id": "test_6_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "mds_sf3b1_ring_sideroblasts",
        "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
        "blasts_percentage": 3,
        "number_of_dysplastic_lineages": 1
      },
      "who_classification": "MDS with low blasts and SF3B1",
      "icc_classification": "MDS with mutated SF3B1",
      "who_derivation": [
        "Retrieved blasts_percentage: 3",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 3, fibrotic: False",
        "SF3B1 mutation detected => MDS with low blasts and SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with low blasts and SF3B1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 3",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 3",
        "SF3B1 mutation detected => MDS with mutated SF3B1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with mutated SF3B1 (ICC 2022)"
      ],
      "who_disease_type": "MDS_SF3B1",
      "icc_disease_type": "MDS_SF3B1",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with low blasts and SF3B1",
        "icc_classification": "MDS with mutated SF3B1",
        "who_category": "MDS_SF3B1",
        "icc_category": "MDS_SF3B1",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.563037",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "SF3B1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "mds_sf3b1_ring_sideroblasts",
        "scenario_description": "MDS with SF3B1 mutation and ring sideroblasts",
        "blasts_percentage": 3,
        "number_of_dysplastic_lineages": 1
      }
    },
    {
      "test_id": "test_7_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "hypoplastic_mds",
        "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
        "blasts_percentage": 8,
        "hypoplasia": true,
        "number_of_dysplastic_lineages": 2
      },
      "who_classification": "MDS with increased blasts 1",
      "icc_classification": "MDS with excess blasts",
      "who_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 8, fibrotic: False",
        "5-9% blasts => MDS with increased blasts 1",
        "Current classification: MDS with increased blasts 1",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with increased blasts 1 (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 8",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "MDS-related genes => AML with myelodysplasia related gene mutation",
        "Blasts <10 => final classification: Not AML, consider MDS classification",
        "No germline predisposition indicated (review at MDT)",
        "Final => Not AML, consider MDS classification",
        "AML ICC classifier indicated that the case is not AML. Switching to MDS ICC classification...",
        "Default classification set to: MDS, NOS",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "blasts_percentage: 8",
        "5-9% blasts => MDS with excess blasts",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS with excess blasts (ICC 2022)"
      ],
      "who_disease_type": "MDS_BLASTS",
      "icc_disease_type": "MDS_BLASTS",
      "are_equivalent": true,
      "difference_analysis": {
        "who_classification": "MDS with increased blasts 1",
        "icc_classification": "MDS with excess blasts",
        "who_category": "MDS_BLASTS",
        "icc_category": "MDS_BLASTS",
        "are_equivalent": true,
        "category_match": true,
        "difference_type": "terminology_only",
        "significance": "minimal",
        "clinical_impact_score": 0,
        "clinical_consequences": [],
        "treatment_implications": [],
        "mrd_implications": [],
        "prognostic_implications": []
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.563083",
      "significance": "minimal",
      "clinical_impact_score": 0,
      "clinical_consequences": [],
      "treatment_implications": [],
      "mrd_implications": [],
      "prognostic_implications": [],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {
          "ASXL1": true
        },
        "MDS_related_cytogenetics": {},
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "hypoplastic_mds",
        "scenario_description": "Hypoplastic MDS - can mimic aplastic anemia",
        "blasts_percentage": 8,
        "hypoplasia": true,
        "number_of_dysplastic_lineages": 2
      }
    },
    {
      "test_id": "test_8_realistic_clinical_scenarios",
      "input_data": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "fibrotic_mds",
        "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
        "blasts_percentage": 15,
        "fibrotic": true
      },
      "who_classification": "MDS, fibrotic",
      "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
      "who_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: Acute myeloid leukaemia, [define by differentiation]",
        "All AML-defining recurrent genetic abnormality flags are false.",
        "No AML-defining abnormalities and blasts <20 => consider reclassification as MDS.",
        "No AML_differentiation provided.",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => Not AML, consider MDS classification",
        "AML classifier indicated that the case is not AML. Switching to MDS classification...",
        "Default classification set to: MDS, unclassifiable",
        "Checking for biallelic TP53: {}",
        "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False, with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False",
        "Retrieved blasts: 15, fibrotic: True",
        "10-19% blasts => MDS with increased blasts 2",
        "Blasts 5-19% with fibrotic marrow => MDS, fibrotic",
        "Current classification: MDS, fibrotic",
        "No germline predisposition indicated (review at MDT)",
        "Final classification => MDS, fibrotic (WHO 2022)"
      ],
      "icc_derivation": [
        "Retrieved blasts_percentage: 15",
        "Default classification set to: AML, NOS",
        "No ICC AML-defining abnormality is True.",
        "No biallelic TP53 conditions met.",
        "No MDS-related genes set to True.",
        "MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality",
        "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification: MDS/AML with myelodysplasia related cytogenetic abnormality",
        "No germline predisposition indicated (review at MDT)",
        "Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)"
      ],
      "who_disease_type": "UNCLASSIFIABLE",
      "icc_disease_type": "AML_MDS_RELATED",
      "are_equivalent": false,
      "difference_analysis": {
        "who_classification": "MDS, fibrotic",
        "icc_classification": "MDS/AML with myelodysplasia related cytogenetic abnormality",
        "who_category": "UNCLASSIFIABLE",
        "icc_category": "AML_MDS_RELATED",
        "are_equivalent": false,
        "category_match": false,
        "difference_type": "major_clinical_impact",
        "significance": "critical",
        "clinical_impact_score": 120,
        "clinical_consequences": [
          "Fundamental disease classification disagreement"
        ],
        "treatment_implications": [
          "Intensive chemotherapy vs supportive care",
          "Stem cell transplant eligibility differs",
          "Clinical trial eligibility differs"
        ],
        "mrd_implications": [],
        "prognostic_implications": [
          "Risk category: Unknown vs Intermediate",
          "Different survival expectations",
          "Different treatment intensity recommendations"
        ]
      },
      "test_focus": "realistic_clinical_scenarios",
      "timestamp": "2025-06-06T20:04:49.563142",
      "significance": "critical",
      "clinical_impact_score": 120,
      "clinical_consequences": [
        "Fundamental disease classification disagreement"
      ],
      "treatment_implications": [
        "Intensive chemotherapy vs supportive care",
        "Stem cell transplant eligibility differs",
        "Clinical trial eligibility differs"
      ],
      "mrd_implications": [],
      "prognostic_implications": [
        "Risk category: Unknown vs Intermediate",
        "Different survival expectations",
        "Different treatment intensity recommendations"
      ],
      "test_case": {
        "AML_defining_recurrent_genetic_abnormalities": {},
        "MDS_related_mutation": {},
        "MDS_related_cytogenetics": {
          "del_5q": true
        },
        "Biallelic_TP53_mutation": {},
        "qualifiers": {},
        "scenario_name": "fibrotic_mds",
        "scenario_description": "Fibrotic MDS - difficult to aspirate marrow",
        "blasts_percentage": 15,
        "fibrotic": true
      }
    }
  ],
  "timestamp": "2025-06-06T20:04:49.563894",
  "total_tests": 8
}